Crossmark

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

Crossref DOI link: https://doi.org/10.1186/s12885-015-1293-y

Published Online: 2015-04-29

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Garcia-Alfonso, Pilar

Chaves, Manuel

Muñoz, Andrés

Salud, Antonieta

García-Gonzalez, Maria

Grávalos, Cristina

Massuti, Bartomeu

González-Flores, Encarna

Queralt, Bernardo

López-Ladrón, Amelia

Losa, Ferran

Gómez, Maria Jose

Oltra, Amparo

Aranda, Enrique
License Information

License valid from 2015-04-29